LPTX

NASDAQ

Leap Therapeutics Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations

News25/Ratings5

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

News · 26 weeks210%

2025-10-262026-04-19

Mix090d

No activity.

Latest news

25 items

161dINSIDER
SEC Form 4 filed by CEO,CFO,Pres.,GC,Treas.&Sec. Onsi Douglas E
4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
161dINSIDER
SEC Form 4 filed by Director Li William
4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
161dINSIDER
SEC Form 4 filed by Director Richard Christian M
4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
161dINSIDER
SEC Form 4 filed by Director Mashiach Nissim
4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
161dINSIDER
SEC Form 4 filed by Director Martin Patricia A.
4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
161dINSIDER
SEC Form 4 filed by Director Schilsky Richard
4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
161dINSIDER
SEC Form 4 filed by Director Loscalzo Joseph
4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
161dINSIDER
SEC Form 4 filed by Director Cavanaugh James H
4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
161dINSIDER
SEC Form 4 filed by Director Mirabelli Christopher
4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
161dINSIDER
SEC Form 4 filed by Director Dietz Thomas John
4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
161dINSIDER
SEC Form 4 filed by Director Oei Khing Djien
4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
161dINSIDER
SEC Form 3 filed by new insider Oei Khing Djien
3 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
162dSEC
SEC Form DEFA14A filed by Leap Therapeutics Inc.
DEFA14A - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
162dSEC
Leap Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
8-K - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
163dSEC
SEC Form 424B5 filed by Leap Therapeutics Inc.
424B5 - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
163dSEC
SEC Form 10-Q filed by Leap Therapeutics Inc.
10-Q - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
163dSEC
Leap Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Other Events
8-K - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
163dPR
Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc., previously known as Leap Therapeutics, Inc. (NASDAQ:LPTX), a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash, today reported financial results for the third quarter of 2025 and a corporate update. As announced earlier today, the Company has changed its name to "Cypherpunk Technologies Inc." from "Leap Therapeutics, Inc." to reflect the strategic focus on acquiring the digital asset, ZEC, participating in the development of Zcash, and the values of privacy and liberty. The Company will begin trading on the Nasdaq Capital Market under the
163dPR
Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy
Khing Oei appointed Chairman of the Board; Will McEvoy appointed Chief Investment Officer and Member of the Board; Cypherpunk Technologies Inc. announces acquisition of 203,775.27 ZEC. CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today announced it will change its name to Cypherpunk Technologies Inc., and unveiled a digital asset treasury strategy to accumulate Zcash's native coin, ZEC. Cypherpunk has to date used $50 million of proceeds from the previously announced private placement to purchase 203,775.27 ZEC at an average purchase price of $245.37 per ZEC. In addition, the company also plans to change its ticker symbol to (NASDAQ:CYPH) as part of t
172dSEC
SEC Form DEFA14A filed by Leap Therapeutics Inc.
DEFA14A - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
172dSEC
SEC Form DEF 14A filed by Leap Therapeutics Inc.
DEF 14A - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
181dSEC
SEC Form PRE 14A filed by Leap Therapeutics Inc.
PRE 14A - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
186dSEC
SEC Form 8-K filed by Leap Therapeutics Inc.
8-K - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
186dPR
Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025
Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high population Increasing DKK1 levels further improved PFS, OS, and ORR advantage for the Sirexatamab Arm Leap to continue supporting development of sirexatamab in DKK1-high CRC patients CAMBRIDGE, Mass., Oct. 20, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced final results from Part B of the DeFianCe study (NCT05480306), a Phase 2 study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy (Sirexatamab Arm) compared to bevacizumab and ch
197dPR
Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy
CAMBRIDGE, Mass., Oct. 9, 2025 /PRNewswire/ -- Leap Therapeutics (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has closed its previously announced private placement led by Winklevoss Capital raising $58,888,888 in cash to initiate a digital asset treasury strategy. At the closing of the transaction, Leap issued (i) 15,212,311 shares of common stock (the "Shares"), (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 80,768,504 shares of common stock, and (ii) warrants to purchase an additional 71,985,605 shares of common stock at an exercise price of $0.5335 per share (the "War